Skip to main content

Table 6 Cluster statistics related to relevant clinical, demographic and genetic data, including treatment use at baseline. Ward`s Euclidean method, Kruskal- Wallis and χ2 test, p < 0.05. Strong sensitization defined as sIgE to respective allergen of > 17.51 kU/L (classes 4–6)

From: Treatment outcome clustering patterns correspond to discrete asthma phenotypes in children

Feature Cluster 1 Cluster 2 Cluster 3 Cluster 4 p value
No of patients N = 58 N = 87 N = 138 N = 64  
Strong sensitization to house dust mite (sIgE d1)—No 18 (31.03%) 40 (45.98%) 73 (52.90%) 31 (48.44%)  < 0.05
Strong sensitization to house dust mite (sIgE d1)—Yes 40 (68.97%) 47 (54.02%) 65 (47.10%) 33 (51.56%)  < 0.05
  Mean (STD) Mean (STD) Mean (STD) Mean (STD)  
% FEV1 predicted at baseline 0.89 (0.20) 0.96 (0.13) 0.82 (0.17) 0.88 (0.15)  < 0.001
% MEF50 predicted at baseline 0.92 (0.22) 1.03 (0.19) 0.79 (0.22) 0.84 (0.24)  < 0.001
FENO at baseline (ppb) 21.5 (23.61) 17.23 (16.15) 23.07 (23.14) 18.59 (13.38)  
Age (yrs) 11.79 (3.39) 10.16 (3.82) 9.98 (3.84) 9.61 (3.64)  < 0.01
Height (cm) 153.05 (17.78) 143.9 (19.11) 143.86 (21.12) 142.23 (21.24)  < 0.05
Disease duration (yrs) 5.72 (3.43) 5.08 (3.84) 4.12 (3.8) 3.45 (3.11)  < 0.001
Total IgE (kIU/L) 686.34 (744.36) 421.95 (578.5) 653.9 (1164.19) 484.79 (516.04)  
Eosinophil absolute count (Dunger) 419.99 (284.96) 418.71 (347.17) 380.16 (305.29) 377.22 (349.65)  
Neutrophil blood count (%) 49.72 (11.26) 50.79 (13.18) 49.57 (12.82) 51.99 (12.96)  
hsCRP (mg/L) 2.58 (6.31) 4.02 (14.45) 3.11 (7.52) 2.57 (3.72)  
Platelets (× 109/L) 291.09 (86.54) 278.68 (108.14) 283.72 (105.47) 257.7 (105.31)  
ICS medium and high doses use from 2nd to 3rd visit, N (%) 30 (51.72%) 32 (36.78%) 51 (36.96%) 38 (59.38%)  < 0.05
SABA use from 2nd to 3rd visit, N (%) 7 (12.07%) 6 (6.90%) 4 (2.90%) 27 (42.19%)  < 0.001
BMI percentile 0–5, N(%) 0 (0) 3 (3.45) 4 (2.9) 3 (4.69)  
BMI percentile 5–85, N(%) 47 (81.03) 53 (60.92) 94 (68.11) 46 (71.88)  
BMI percentile > 85, N(%) 11 (18.87) 31 (35.63) 40 (28.99) 15 (23.43)  
Gene_rs37973—GG 13 (22.41%) 13 (14.94%) 15 (10.87%) 12 (18.75%)  < 0.05
Gene_rs37973—GA 18 (31.03%) 48 (55.17%) 70 (50.72%) 34 (53.12%)  < 0.05
Gene_rs37973—AA 27 (46.55%) 26 (29.89%) 53 (38.41%) 18 (28.12%)  < 0.05